Fig. 3From: Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trialOverall CAB performance with prognostic and predictive values in HR+/HER2− early breast cancer patients. A DRFi was stratified into three groups: CAB high-risk, CAB low-risk in the exemestane arm, and CAB low-risk in the sequential arm. P value was adjusted using the method of Benjamini-Hochberg (BH). B Schematic overall performance of CABBack to article page